Fresenius Medical Care (FMS) Earnings Dates, Call Summary & Reports

Q: When does Fresenius Medical Care Corp. (FMS) report earnings?

Fresenius Medical Care Corp. (FMS) is schdueled to report earning on May 05, 2026, TBA (Confirmed).

Q: What is Fresenius Medical Care Corp. (FMS) earnings time?

Fresenius Medical Care Corp. (FMS) earnings time is at May 05, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is FMS EPS forecast?

FMS EPS forecast for the fiscal quarter 2026 (Q1) is 0.54.

Compare

361 Followers

Earnings Data

Report Date

May 05, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.54

Last Year’s EPS

0.48

Same Quarter Last Year

Analyst Consensus

Hold

Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 24, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call highlights a strong 2025 performance with significant margin expansion, robust cash generation, successful execution of transformation programs (FME25+) and a Value-Based Care turnaround. These positives are tempered by notable near-term headwinds and one-time contributions (TDAPA and binders) that raise the 2026 comparable base, China regulatory pressures, flat U.S. treatment volumes and transitional costs from the large-scale 5008X rollout and IT investments. Overall, the company presents a credible long-term growth and margin path while acknowledging a transitional 2026.

Company Guidance

Management guided to 2026 that group revenue should be broadly flat with operating income roughly flat (mid‑single‑digit percent upside/downside) and a group margin range of 10.5%–12%, noting stronger H1 before TDAPA benefits phase out in H2; assumptions include flat U.S. same‑market treatment growth in 2026 (with a return to >2% as mortality normalizes), a large‑scale 5008X rollout replacing ~20% of the installed base (training >7,200 nurses/technicians and transitioning ~36,000 patients across 28 states) that will create an OpEx rollout headwind and ~‑€100m higher intersegment eliminations, Value‑Based Care revenue reduction of ~€300m (no expected earnings hit), business growth of €250–350m, incremental FME25+ savings of €250m with related one‑time costs of €350m, inflationary pressure of €200–300m (including ~3% net labor), regulatory headwinds of €150–200m (including TDAPA/phosphate binder effects), portfolio optimization dragging ~30 bps, corporate costs of €200–220m, net financial result of −€340–360m, an effective tax rate of 22–24%, and an FX assumption of $1.18/€; medium‑term targets reiterated were operating income CAGR 3%–7% through 2028 (implied low‑teens CAGR excluding TDAPA noise), FME25+ cumulative savings target of €1.2bn by end‑2027 (€804m realized to date, €238m incremental in 2025), and 2030 aspirations of lower‑to‑mid single‑digit revenue CAGR for Care Delivery, mid single‑digit for Care Enablement, mid‑teens group margin and a low single‑digit OI margin for Value‑Based Care.

Strong full-year profitability and margin expansion

2025 operating income grew 27% and the group delivered a 2025 group margin of 11.3%; Q4 margin jumped to 13.9% (a 430 basis point YoY improvement), driven by contributions across all three segments.

Exceptional fourth-quarter revenue and earnings growth

Q4 organic revenue growth was 8% (7% at constant currency) and adjusted operating income increased ~53% on a constant currency basis; EPS grew ~68% in Q4, supported by share buybacks.

Cash generation and capital returns

Operating cash flow in 2025 was EUR 2.7 billion. Company repurchased ~EUR 585 million of shares in 2025 (first tranche of EUR 1bn program) and initiated an additional tranche (~EUR 414 million in Jan). Proposed dividend for 2025 is EUR 1.49 (+3% vs 2024, ~33% payout).

FME25+ transformation savings and program progress

Accumulated sustainable savings reached EUR 804 million; 2025 delivered EUR 238 million incremental sustainable savings (ahead of ~EUR 220m target). Company expects incremental savings of EUR 250 million in 2026 and total sustainable savings of EUR 1.2 billion by end-2027 (with EUR 400 million costs across 2026–27).

Value-Based Care turnaround

Value-Based Care achieved 42% organic revenue growth in Q4, produced positive operating income of EUR 29 million in Q4, and finished 2025 at breakeven (EUR 3 million operating income vs a EUR 28 million loss in 2024).

Care Delivery operational progress and product rollout

Care Delivery achieved 7% organic revenue growth (8% in U.S.), Q4 margin improved to 16.4% (up 440 bps). Company launched the 5008X CAREsystem soft launch in the U.S. in 2025 and initiated large-scale rollout in 2026 targeting ~20% of installed base replacement this year (training ~7,200 staff, transitioning ~36,000 patients).

Leverage and balance sheet improvement

Net leverage improved from 3.4x at end-2022 to 2.5x at end-2025, moving to the lower end of the target corridor (target band 2.5x–3x); net debt and lease liabilities reduced ~6% vs prior period.

Fresenius Medical Care (FMS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FMS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 05, 2026	2026 (Q1)	0.54 / -	0.476	―	―	―
Feb 24, 2026	2025 (Q4)	0.65 / 0.85	0.478	77.41% (+0.37)
Nov 04, 2025	2025 (Q3)	0.59 / 0.63	0.447	41.39% (+0.18)
Aug 05, 2025	2025 (Q2)	0.51 / 0.53	0.378	39.15% (+0.15)
May 06, 2025	2025 (Q1)	0.43 / 0.48	0.361	31.86% (+0.11)
Feb 25, 2025	2024 (Q4)	0.42 / 0.48	0.476	0.42% (<+0.01)
Nov 05, 2024	2024 (Q3)	0.38 / 0.45	0.303	47.52% (+0.14)
Jul 30, 2024	2024 (Q2)	0.37 / 0.38	0.322	17.39% (+0.06)
May 07, 2024	2024 (Q1)	0.28 / 0.36	0.291	24.05% (+0.07)
Feb 20, 2024	2023 (Q4)	0.44 / 0.48	0.456	4.39% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FMS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 24, 2026	$24.59	$22.66	-7.85%
Nov 04, 2025	$26.35	$24.29	-7.82%
Aug 05, 2025	$24.94	$24.42	-2.09%
May 06, 2025	$25.14	$26.90	+7.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fresenius Medical Care Corp. (FMS) report earnings?

Fresenius Medical Care Corp. (FMS) is schdueled to report earning on May 05, 2026, TBA (Confirmed).

What is Fresenius Medical Care Corp. (FMS) earnings time?

Fresenius Medical Care Corp. (FMS) earnings time is at May 05, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FMS EPS forecast?

FMS EPS forecast for the fiscal quarter 2026 (Q1) is 0.54.